12/03/2021 | Press release | Distributed by Public on 12/03/2021 14:17
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 29, 2021
FUSE MEDICAL, INC.
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction
|1565 North Central Expressway|
|Suite 220Richardson, Texas||75080|
|(Address of Principal Executive Offices)||(Zip Code)|
Registrant's Telephone Number, Including Area Code: (469) 862-3030
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
on which registered
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Section 1 - Registrant's Business and Operations
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 29, 2021, William E. McLaughlin, III resigned as Chief Financial Officer and as a Director of the Board of Fuse Medical, Inc. (the "Company") as well as from all other positions Mr. McLaughlin held with the Company and its subsidiaries. Mr. McLaughlin had no disagreements with the Company on any matter related to the Company's operations, policies or practices.
On December 3rd, 2021, Fuse Medical, Inc engaged CFO Consulting Partners, LLC to provide interim Chief Financial Officer (CFO) services, which include oversight and support to the current financial and operational processes and capabilities of the Company, while also providing organizational assessments and tool development while the Company searches for a permanent CFO.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|Date: November 29, 2021||By:||
/s/ Christopher C. Reeg
|Christopher C. Reeg,|
|Chief Executive Officer and Director|